A Phase Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent
Status:
COMPLETED
Trial end date:
2024-12-27
Target enrollment:
Participant gender:
Summary
It is a randomized, double-blinded, parallel, single-dose, Phasecomparative study to evaluate the pharmacokinetics and safety of QL2108 to Dupixent in healthy Chinese adult subjects. A total of 198 healthy subjects are planned to be included and randomized at a ratio of 1:1 to receive single 300mg/2.0ml QL2108 injection or Dupixent.